🇺🇸

US SEC Filing Intelligence

· daily

Contract Option Exercises — April 02, 2026

Two bullish contract exercises totaling $352.8M obligated value highlight sustained U.S. government demand for health infrastructure, with SoldierPoint Digital Health securing $237.7M VA IT services (upside to $862.8M) and Hensel Phelps awarded $115.1M NIH vivarium construction. Both firm-fixed-price delivery orders via full/open competition signal revenue visibility for non-small businesses, though FFP structures expose cost overrun risks. Investors should prioritize monitoring option exercises and extensions amid zero outlays (SoldierPoint) and excess outlays (Hensel Phelps).

2 total filings
· daily

Federal IT & Cybersecurity Contracts — April 02, 2026

SoldierPoint Digital Health, LLC won a $237.7M obligated VA delivery order for IT architecture and application development (NAICS 541512), with base + options ceiling of $862.8M through potential 2029. This underscores robust federal healthcare IT demand but carries execution risks from firm-fixed pricing and $58.9M in subawards with zero outlays to date. Investors should monitor option exercises for revenue upside amid subcontractor dependencies.

1 total filings
· daily

Mega Contracts Monitor ($100M+) — April 02, 2026

Two bullish mega-contracts totaling $353M highlight sustained federal demand for health-related IT services and biomedical construction, with SoldierPoint's $238M VA award (potential $863M) offering massive upside via options and Hensel Phelps' $115M NIH project showing strong cash flow ($119M outlaid). Firm-fixed-price structures introduce execution risks, but no bearish signals emerge. Investors should monitor option exercises and outlay ramps for revenue acceleration in gov-health sectors.

2 total filings
· daily

High-Value Federal Grants ($5M+) — April 02, 2026

Two high-value federal contracts totaling $353M obligated value signal robust demand for health infrastructure, with VA awarding $238M (potential $863M ceiling) to SoldierPoint for IT services and NIH $115M to Hensel Phelps for vivarium construction. Both firm-fixed-price deals to non-small businesses via open competition underscore bullish execution momentum amid $119M outlays already for Hensel Phelps, though FFP structures amplify cost overrun risks. Cross-cutting upside lies in $625M potential options/extensions through 2029, prioritizing health IT and biomedical facilities.

2 total filings
· daily

General Federal Contracts — April 02, 2026

Two bullish federal contracts totaling $353M underscore sustained HHS/VA investment in healthcare digital infrastructure ($238M obligated, $863M potential) and biomedical facilities construction ($115M). Firm fixed price structures expose contractors to cost overrun risks, with SoldierPoint showing no outlays yet and Hensel Phelps outlays exceeding obligations by 3%. Cross-cutting opportunities lie in option exercises and extensions to 2029, signaling multi-year revenue ramps for non-small business contractors.

2 total filings
· daily

S&P 500 Technology Sector SEC Filings — April 02, 2026

The 22 filings from USA S&P 500 Technology stream (April 2, 2026) are dominated by 10 proxy-related documents (DEF 14A/DEFA14A) for May 2026 AGMs, reflecting routine governance with neutral sentiment across NCS Multistage, Iridium, Radian Group, Apple Hospitality REIT, and Community Health Systems; no major disputes or declines noted. Executive transitions in 5 companies (Optimum Communications EVP demotion/retirement with $3.6M payout, Zoom COO resignation May 8, Broadcom CFO retirement Jun 12 with Alphabet CAO successor, Esquire director health-related exit, CareView ongoing debt amendments) are neutral, signaling stable leadership changes without disagreements. Positive financing and operational highlights include ISQ Open Infrastructure's $28.3M unregistered equity raise and $0.34/share distribution (May 5), Immunic's Phase 3 enrollment completion (2,221 patients, topline end-2026), CHS's 2025 net income turnaround to $509M from -$516M loss despite -1.2% YoY revenue to $12.5B, $3.3B debt reduction, and Aditxt Nasdaq compliance confirmation ($4M equity). Apple Hospitality reported 2025 buybacks of 5M shares, hotel portfolio optimization across 84 markets. Portfolio-level trends show sparse but improving financials (e.g., CHS EBITDA margin flat 12.2%, positive FCF), capital returns via buybacks/debt paydown/distributions, and catalysts like biotech data; implications favor monitoring leadership stability and May events amid low volatility.

12 high priority 10 medium 22 total filings
· daily

Nasdaq 100 Stocks SEC Filings — April 02, 2026

Across 26 NASDAQ-100 related SEC filings dated April 2, 2026, dominant themes include a surge in proxy statements (10+ DEF/DEFA14A) signaling the onset of 2026 proxy season with clustered annual meetings in May, alongside notable executive transitions at tech leaders like Zoom (COO resignation), Alphabet (controller resignation), Broadcom (CFO retirement with Alphabet alum appointment), and Booking Holdings (new CAO). Financial highlights reveal mixed performance: Community Health Systems achieved a dramatic net income turnaround to +$509M from -$516M loss YoY despite -1.2% revenue decline, Trilogy Metals saw Q1 FY2026 loss double to $7.1M YoY amid higher expenses, Tesla reported flat +1% YoY Q1 vehicle deliveries at 358K, and Starbucks closed a positive China JV ceding 60% control for liquidity. Positive catalysts include Immunic's Phase 3 enrollment completion with topline data by end-2026, Booking's 25-for-1 stock split, and Aditxt's Nasdaq compliance resolution. Portfolio-level trends show neutral-to-positive sentiment (8 positive, 12 neutral, 4 mixed, 2 bearish implied), with healthcare/mining outliers in deteriorating losses/revenues but debt reductions/buybacks signaling capital discipline; no broad margin compression evident but limited QoQ/YOY data (e.g., Trilogy cash -7.4% QoQ, CYH EBITDA margin flat 12.2%). Implications favor monitoring May proxy votes for equity plans/governance and Q1 earnings catalysts like Tesla's April 22 webcast for deeper financials.

15 high priority 11 medium 26 total filings
· daily

S&P 500 Financials Sector SEC Filings — April 02, 2026

Across 50 SEC filings from the USA S&P 500 Financials stream (with cross-sector exposure including REITs, financial data providers, pharma/mining outliers), sentiment is mixed with 12 positive, 14 mixed, and 10 negative summaries; period-over-period trends reveal revenue growth averaging +18% YoY in outperformers like Pharming (+26.6% to $376M), Dynaresource (+25.7% to $58M), and FactSet (+7% to $611M Q), but sharp declines in underperformers like Airsculpt (-15.8% FY to $152M), LightInTheBox (-12.2% to $224M), and Lindsay (-16% Q2 to $158M). Capital allocation emphasizes buybacks (News Corp $1B program, FactSet $303M YTD, Lindsay $25M Q2, Oceaneering $40M) and dividends (Burford 6.25¢ final), signaling shareholder returns amid volatility; M&A/SPAC activity is robust with accretive deals like Kodiak's $587M DPS acquisition (+395MW capacity) and Crown Reserve's $1B EV Carvix combo ($80M PIPE). Forward-looking catalysts cluster in May 2026 AGMs (20+ filings, e.g., Sylvamo May15, Burford May13) and guidance reaffirms (ESAB, Sally Beauty FY26); debt actions improve liquidity (Terra exchange to 2029 notes, Transocean $358M retire/$0.75B 2026 plan, CareView maturity to Jun30). Portfolio implications: overweight accretive M&A/REIT restructurings, underweight going concerns (Mannatech, Algorhythm); sector shows resilience in financial metrics (e.g., FactSet op CF +28%) despite broader declines.

28 high priority 22 medium 50 total filings
· daily

S&P 500 Consumer Staples Sector SEC Filings — April 02, 2026

Across 50 filings from the USA S&P 500 Consumer Staples intelligence stream (though diverse sectors represented), proxy statements dominate (over 60%), signaling the onset of 2026 proxy season with annual meetings clustered in May-June 2026, emphasizing governance, director elections, auditor ratifications, and say-on-pay votes. Positive outliers include accretive M&A (Kodiak's $587M acquisition adding 395MW capacity, immediately EPS/DCF accretive), record performances (Morgan Stanley's $70.6B 2025 revenues, $10.21 EPS, 21.6% ROTCE; BlackRock ESG's 86% cumulative return since 2023 vs. 56% benchmark), and capital optimization (CVGI's $16M sale-leaseback delevering facility). Limited period-over-period data shows bullish trends like Cleveland-Cliffs' 43% safety incident reduction since 2020 and Diamond Hill's $25.9B AUM (led by Consumer Staples like Costco at $57M). No widespread margin compression or revenue declines; neutral sentiment prevails (70% of filings) with positive M&A/capital raises (10%). Consumer Staples exposure indirect via 13F top holding Costco ($57M, 57k shares). Implications: Low sector distress, focus on governance catalysts and M&A for alpha; monitor May meetings for votes.

27 high priority 23 medium 50 total filings
· daily

S&P 500 Industrials Sector SEC Filings — April 02, 2026

The 50 filings from USA S&P 500 Industrials stream reveal a dominant proxy season theme with 25+ DEF 14A/DEFA14A filings for May-June 2026 annual meetings, emphasizing strong 2025 performances, board elections, equity plan approvals, and auditor ratifications amid positive sentiments in 70% of cases. Period-over-period trends show robust growth in select industrials like Acuity Inc. (H1 sales +12.3% YoY to $2.2B, net income +18% to $217M) and transportation (Norfolk Southern HQ lease renewal $499M over 5 years), contrasted by losses in Pharvaris (+31% YoY net loss to €176M) and Pheton (net loss ballooning to $5.1M). Capital allocation shines with Acuity's $106M buybacks, 18% dividend hike, Phillips 66's $3.1B returns (>50% cash flow), and debt reductions (Acuity LT debt -22% to $697M). M&A/integration activity (Associated Banc merger, Bed Bath TBHC acquisition at 0.1993x ratio) and defense catalysts (Kratos share authorization +25% to 245M, Cocrystal FDA Fast Track) signal conviction, while cash declines (Acuity -36% to $273M, Pheton -76%) flag liquidity risks. Forward-looking catalysts cluster in Q2 2026 meetings and Sept PDUFA, positioning industrials for governance-driven upside amid mixed sentiment (positive in 40%, neutral 40%). Portfolio-level, 6/10 financial reporters show avg +18% revenue growth but variable margins (+20% op profit Acuity vs compressions elsewhere), implying selective buying in growth outliers.

27 high priority 23 medium 50 total filings
· daily

S&P 500 Energy Sector SEC Filings — April 02, 2026

The S&P 500 Energy stream filings highlight proxy season convergence with four companies (Phillips 66, Dorchester Minerals, Kinder Morgan) scheduling 2026 Annual Meetings for May 13, emphasizing governance, director elections, compensation votes, and auditor ratifications amid record dates in March. Devon Energy advances its transformative merger with Coterra Energy, clearing HSR antitrust review on April 1, 2026, positioning for Q2 close and enhanced scale in oil/gas production. Phillips 66 showcases robust 2025 performance with record refining yields, NGL volumes, crude utilization, $3.1B shareholder returns (over 50% of net operating cash flow ex-WC), 10% dividend hike, strategic acquisitions (EPIC NGL/Coastal Bend, WRB Refining), and debt reduction target to $17B by 2027. Lion Copper & Gold reports FY2025 net income swing to $4.4M profit from $4.7M loss, driven by $26.4M deconsolidation gain, but operating loss ballooned to $16.7M from $3.8M on higher G&A (+101% YoY) and share-based comp (+476% YoY), with cash plummeting 70% YoY to $2.4M and negative operating cash flow of $13.2M vs prior positive. Kinder Morgan and Dorchester filings are routine proxies with neutral sentiment, low materiality. Portfolio-level trends show capital returns strength at Phillips contrasting Lion's cash burn; M&A momentum via Devon/Phillips deals signals consolidation. Implications: Near-term catalysts in shareholder votes and merger close favor bullish positioning in Devon/Phillips, caution on Lion liquidity.

4 high priority 4 medium 8 total filings
· daily

US Material Events SEC 8-K Filings — April 02, 2026

Across 50 SEC filings from April 2, 2026, a dominant theme is widespread executive transitions (22 instances), with 12 positive appointments of experienced leaders (e.g., CFOs from major firms) signaling stability and growth focus, contrasted by 10 resignations/retirements without noted disagreements. M&A and financing activity surges positively, including accretive acquisitions (Kodiak +395MW capacity, immediate EPS accretion; Nuveen portfolio diversification top 10 from 11% to 9%) and new credit facilities (Caris $400M term loan + $300M delayed draw; Option Care +$450M revolver to $850M total), enhancing liquidity amid neutral-to-positive sentiment in 70% of high-materiality (>8/10) events. Limited period-over-period data shows mixed financials: Ashford Hospitality pro forma revenue -1.6% YoY to $1.087B but net loss improved 16% to $157M; Southland settlement adds ~$26.5M Sureties payout post-$57.8M prior. Distressed signals emerge in 4 cases (Borealis forbearance on $16M obligations, multiple defaults; Cardiff severance $1.3M+), but forward-looking catalysts abound (OS Therapies OST-HER2 approvals H2 2026 + PRV potential; PCAP/BDC V close Q2 2026). No broad insider trading patterns, but capital allocation leans to debt refinancings/exchanges (Terra $25.6M secured notes) over dividends/buybacks. Sectorally, biotech/pharma shows funding optimism (OS Therapies $5.25M raise + $4M non-dilutive), REITs portfolio optimization, energy M&A expansion. Overall, bullish for growth-oriented firms, monitor distress outliers for short opportunities.

50 high priority 50 total filings
· daily

Dow Jones 30 Stocks SEC Filings — April 02, 2026

Across 50 SEC filings from the USA Dow Jones 30 intelligence stream (April 2, 2026), proxy statements dominate (over 25 DEF/DEFA14A filings) signaling peak annual meeting season in May 2026, with neutral sentiment on governance but positive undertones in board refreshes and comp approvals. Key period trends show selective revenue acceleration (e.g., Pharming +26.6% YoY to $376M, Venu sales +62% YoY to $126M) amid flat/declining cases (Venu rev flat, Lovesac internet -2%, other -37%), with margin pressures in retail (Lovesac -210 bps to 56.4%) offset by profitability swings (Pharming to +$26M op profit). M&A activity surges bullish (Kodiak accretive $587M deal +395MW capacity, Soluna $53M wind farm, Clear Channel $2.43/share buyout), while trusts/BDCs face wind-downs (MV Oil terminates June 30, Nuveen liquidation). Biotech mixed with expansions (Roivant Phase 3 trials) but failures (Immunovant TED trials miss). Capital allocation leans defensive (Lovesac $6M buybacks, dividends in Solstice), no broad insider trading patterns but leadership changes signal transitions (Sally Beauty CFO appt, Fiserv CEO). Portfolio implications: Favor M&A targets and revenue growers for near-term alpha, monitor May catalysts and trust liquidations for volatility.

28 high priority 22 medium 50 total filings
· daily

US SEC Filings Daily Market Digest — April 02, 2026

Across 50 SEC filings from April 2, 2026, key themes include a surge in proxy statements signaling the 2026 AGM season with May-heavy catalysts (e.g., Sylvamo, Hyatt, Burford Capital), robust M&A and deal activity in SPACs/energy (Suncrete exchange, Kodiak $587M acquisition, Crown Reserve $1B BCA), and mixed financial results with healthcare/biotech growth (Pharming +26.6% YoY revenue) offset by declines in consumer/services (Airsculpt -14.6% Q4 revenue, LightInTheBox -12.2% 2025 revenue). Period-over-period trends show 7/20 companies with revenue growth averaging +18% YoY (e.g., DYNARESOURCE +25.7%, FactSet +7%), but 6/20 reported declines averaging -14% with margin stability or compression (Airsculpt EBITDA down FY but Q4 up); capital allocation leans bullish with buybacks (News Corp $1B program, FactSet $303M six-month, Lindsay $55.5M YTD) and debt management (Transocean retiring $750M 2026). Positive swings to profitability in Pharming/Pharma (+op profit) and DYNARESOURCE contrast going concern doubts (Mannatech, Algorhythm). Market implications favor monitoring energy/services turnarounds and healthcare outperformers amid stable guidance reaffirmations (ESAB, Sally Beauty). Portfolio-level: Energy/mining outliers positive on backlog/capex, while microcaps flag liquidity risks.

29 high priority 21 medium 50 total filings
· daily

S&P 500 Consumer Discretionary Sector SEC Filings — April 02, 2026

The 50 filings reveal a heavy focus on proxy season preparations for May 2026 AGMs across diverse issuers, including director elections, say-on-pay approvals, auditor ratifications, and equity plan expansions, signaling governance stability amid S&P 500 Consumer Discretionary peers. Period-over-period trends show mixed results: revenue growth in 4/50 (FactSet +7% YoY to $611M Q, BBB Foods +36.1% YoY to Ps78B, FreeCast gross profit +77% YoY despite revenue -4%), but profitability challenges (FactSet NI -8% YoY, BBB operating loss widened 150.8% YoY, Ashford pro forma revenue -1.6% but loss improved). Capital allocation leans shareholder-friendly with FactSet $303M buybacks (OCF +28% YoY), Burford 6.25¢ dividend (June payable), and Booking 25:1 stock split effective April 2. Leadership churn prominent (12/50 appointments/retirements, e.g., Booking CAO, Oportun interim CEOs), with financings (Fibro $3M offering, Caris $400M loan) and M&A (Ashford $24.8M hotel sale net, Marine Products merger pro forma EPS $0.40). No widespread insider trading patterns, but positive sentiments in 10/50 (e.g., board additions). Sector implications: monitor May catalysts for governance risks, favor revenue growers like FactSet amid margin pressures; portfolio trend of improving cash flows (FreeCast ops burn -22% YoY) supports buybacks/dividends over reinvestment.

26 high priority 24 medium 50 total filings
· daily

S&P 500 Healthcare Sector SEC Filings — April 02, 2026

Across 50 filings in the USA S&P 500 Healthcare intelligence stream (with broader financial and sector crossovers), dominant themes include a heavy proxy season with 15+ DEF 14A/DEFA14A filings scheduling virtual annual meetings in May 2026 for director elections, auditor ratifications, and equity plan approvals; frequent C-level transitions (9 CFO/COO/CEO changes or appointments); and financing maneuvers like new $400M+ term loans and maturity extensions. Period-over-period trends show selective revenue acceleration (e.g., Vertex $12B total 2025 revenues driven by CF franchise; BD Q1 FY2026 revenues +3.5% YoY to $4.486B, GAAP op income +66% to $468M) amid mixed adjusted metrics (BD adj EPS -10.1% YoY) and comp variances (ENB PEO +3% YoY to $604K, NEOs -39% to $335K). Healthcare-specific highlights feature biotech trial catalysts (Roivant brepocitinib PDUFA Q3 2026 despite Immunovant Phase 3 failures) and device/financing positives (Caris $400M term loan, BD momentum in CASGEVY/JOURNAVX). Capital allocation leans toward equity incentives and buybacks ($1B News Corp program), with neutral-to-positive sentiment (60%+ positive/neutral). Portfolio implications: monitor May proxy outcomes for governance shifts and Q2/Q3 biotech catalysts amid leadership churn signaling potential strategic pivots.

30 high priority 20 medium 50 total filings
· daily

US Executive Compensation Proxy SEC Filings — April 02, 2026

Across 50 DEF 14A proxy statements filed April 2, 2026, for 2026 AGMs primarily in mid-May, companies overwhelmingly highlight robust 2025 performance with revenue growth averaging 7-13% YoY where reported (e.g., Equinix +5%, Cohu +13%, Oceaneering +5%), strong shareholder returns via $569M at Empire State Realty, $450M buybacks at Primerica, and dividend increases at Phillips 66 (+10%), UDR (+1.2% for 213th consecutive), and Solstice (first dividend March 2026). Executive compensation is heavily performance-tied (e.g., 95% at-risk for Equinix CEO, 88% Iridium CEO), with governance features like clawbacks, stock ownership (CEO 6x salary at Iridium/First Solar), and independent boards prevalent; sentiments skew positive/neutral (38/50), mixed in 4 cases with declines (Primerica Term Life -10.4% policies, Cohu GAAP loss $(1.59)/share). Portfolio-level trends show margin expansion in select cases (Tenable +140 bps, Waste Connections outsized), capital allocation favoring buybacks/dividends over M&A in most, but outliers like Horizon Space SPAC deadline extension signal risks; implies broad market resilience but watch REITs/financials for relative outperformance amid clustered AGM catalysts May 12-22.

50 high priority 50 total filings
· daily

US IPO Pipeline SEC S-1 Filings — April 02, 2026

Three S-1 filings on April 2, 2026, signal a nascent IPO pipeline resurgence, featuring a blank-check SPAC (Churchill Capital Corp XII), a multi-geography operating company (TG-17, Inc.), and a consulting firm (Invech Holdings, Inc.), all with high materiality (9-10/10). Limited period-over-period data shows TG-17's balance sheets for Dec 31, 2024 vs 2025 with ongoing operations across US/Israel/France, but no YoY revenue/margin trends disclosed; subsequent events include stock issuances Jan-Mar 2026 indicating capital raises amid customer concentration risks. Churchill's sponsor commitment via 11.5M founder shares (post 2.875M surrender on Mar 16, 2026) and 350k private units highlights SPAC alignment, while Invech flags substantial going concern doubts with no adjustments. Neutral sentiment dominates (2/3 filings), but mixed for Invech underscores pre-IPO risks; no insider trading patterns, forward guidance, or capital returns noted across filings. Portfolio-level theme: High-risk IPO candidates with dilution potential from cheap founder shares/preferred stock, warranting watch for effectiveness and pricing catalysts amid neutral-to-mixed outlook.

3 high priority 3 total filings
· daily

Global High-Priority Regulatory Events — April 02, 2026

Across 50 filings in the Global High Priority Market Events stream (US SEC focus, April 2, 2026), dominant themes include SPAC/business combinations (Suncrete, Crown Reserve), debt refinancings/exchanges (Caris, Terra Property), M&A (Kodiak), and restructuring schemes (Hindware, Aster DM, Narayana), signaling portfolio-level deleveraging and consolidation amid critical events like bankruptcies/insolvencies. Period-over-period trends show mixed financial health: strong revenue growth in biotech/pharma (Pharming +26.6% YoY to $376M, DYNARESOURCE +25.7% to $58M) and services (FactSet +7% YoY to $611M Q1), but sharp declines in ecommerce (LightInTheBox -59.5% YoY to $255M) and persistent losses (Pharvaris net loss +31% YoY to €176M); margins stable/improving in Pharming (~88%) but compressing elsewhere. Capital allocation leans toward buybacks (FactSet $303M H1) and dividends (Burford 6.25¢), with insider conviction limited but positive executive hires (Booking, ESAB, Sally Beauty). Forward-looking catalysts cluster in H2 2026 (OS Therapies approvals) and May AGMs, implying near-term volatility but alpha in accretive deals. REITs (Ashford, Service Properties) show asset sales and share increases for flexibility, while healthcare schemes (15/50 filings) indicate restructuring tailwinds. Overall, bullish on biotech/energy M&A, bearish on microcaps with going concerns.

50 high priority 50 total filings